Intermittent bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) maintains viral suppression in real life in controlled HIV-infected patients

被引：0
|
作者：
Sellem, B. [1 ]
Abdi, B. [2 ]
Peytavin, G. [3 ]
Tubiana, R. [1 ]
Valantin, M. -A. [1 ]
Seang, S. [1 ]
Schneider, L. [1 ]
Faycal, A. [1 ]
Soulie, C. [2 ]
Marcelin, A. -G. [2 ]
Katlama, C. [1 ]
Pourcher, V. [1 ]
Palich, R. [1 ]
机构：
[1] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP,Infect Dis Dept,INSERM 1136, Pierre Louis Epidemiol & Publ Hlth Inst iPLESP, Paris, France
[2] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP,Virol Dept,INSERM 1136, Pierre Louis Epidemiol & Publ Hlth Inst iPLESP, Paris, France
[3] Univ Paris, Bichat Claude Bernard Hosp, AP HP, Pharmacol Toxicol Dept,IAME,INSERM,UMRS 1137, Paris, France
来源：
HIV MEDICINE | 2021年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE2/23
引用
收藏
页码：90 / 91
页数：2
相关论文
共 50 条
  • [21] Real-world experience of bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) in a diverse urban HIV clinic cohort
    Doyle, C.
    Moriarty, M.
    Devitt, E.
    HIV MEDICINE, 2020, 21 : 18 - 18
  • [22] Experience from a real-life cohort: outcome of 984 HIV infected patients treated with bictegravir/emtricitabine/tenofovir alafenamide in Hospital Clinic, Barcelona
    Rojas Lievano, J.
    Berrocal, L.
    Inciarte, A.
    De la Mora, L.
    Gonzalez-Cordon, A.
    Martinez-Rebollar, M.
    Laguno, M.
    Torres, B.
    Ugarte, A.
    Chivite, I.
    Leal, L.
    Ambrosioni, J.
    Blanco, J.
    Martinez Chamorro, E.
    Mallolas, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 24 - 25
  • [23] Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults
    Orkin, C.
    Sax, P.
    Arribas, J.
    Gupta, S.
    Martorell, C.
    Stephens, J.
    Stellbrink, H-J
    DeJesus, E.
    Maggiolo, F.
    Huang, H.
    Acosta, R.
    Brainard, D.
    Collins, S.
    Martin, H.
    HIV MEDICINE, 2020, 21 : 18 - 18
  • [24] Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults
    Orkin, C.
    Sax, P. E.
    Arribas, J.
    Gupta, S.
    Martorell, C.
    Stephens, J. L.
    Stellbrink, H-J
    Dejesus, E.
    Maggiolo, F.
    Huang, H.
    Acosta, R.
    Brainard, D. M.
    Collins, S. E.
    Martin, H.
    HIV MEDICINE, 2019, 20 : 94 - 95
  • [25] Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) single-tablet regimen in HIV-1-infected children (6 to <12 years)
    Cotton, M.
    Liberty, A.
    Rodriguez, C. A.
    Chokephaibulkit, K.
    Kosalaraksa, P.
    Hellstrom, E.
    Natukunda, E.
    Wong, P.
    Majeed, S. R.
    Quirk, E.
    Graham, H.
    Pikora, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 38 - 39
  • [26] Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected adult patients in routine clinical practice-6 months results of the BICSTaR cohort
    Esser, S.
    Jessen, H.
    Schneider, J.
    Schellberg, S.
    Stellbrink, H-J
    Waizmann, M.
    Hillenbrand, H.
    Bilbao, P.
    Schreiber, S.
    Thorpe, D.
    Ramroth, H.
    Haubrich, R.
    Heinzkill, M.
    HIV MEDICINE, 2019, 20 : 61 - 61
  • [27] Week 48 outcomes from the BRAAVE 2020 study: a randomised switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in African American adults with HIV
    Hagins, D.
    Kumar, P.
    Wurapa, A.
    Brar, I.
    Berger, D.
    Osiyemi, O.
    Hileman, C.
    Ramgopal, M.
    McDonald, C.
    Blair, C.
    Andreatta, K.
    Collins, S. E.
    Brainard, D.
    Gohlar, G.
    Martin, H.
    HIV MEDICINE, 2021, 22 : 33 - 34
  • [28] Longer-term (96-week) efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in women
    Kityo, C.
    Hagins, D.
    Koenig, E.
    Avihingsanon, A.
    Chetchotisakd, P.
    Supparatpinyo, K.
    Gankina, N.
    Pokrovsky, V.
    Voronin, E.
    Stephens, J. L.
    DeJesus, E.
    Wang, H.
    Acosta, R.
    Brainard, D.
    Martin, H.
    Makadzange, T. A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 4 - 4
  • [29] Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir
    Calza, Leonardo
    Bon, Isabella
    Pensalfine, Giulia
    Vitale, Salvatore
    Appolloni, Lucia
    Viale, Pierluigi
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2022, 91 (04) : E9 - E11
  • [30] Comparing lamivudine plus dolutegravir and bictegravir/emtricitabine/ tenofovir alafenamide in antiretroviral therapynaive HIV-infected patients: preliminary results from clinical practice
    Long, H.
    HIV MEDICINE, 2023, 24 : 105 - 106
12345